The Bull Case For Novavax (NVAX) Could Change Following Shah Capital’s Activist Governance Challenge - Learn Why

• On May 15, 2026, Shah Capital Management disclosed that it had sent an “Elevating Novavax” presentation to Novavax’s board, criticizing leadership over marketing since 2023, the Sanofi partnership, capital markets decisions, and executive pay practices.
• This intervention signals rising shareholder pressure around governance and capital allocation, potentially increasing expectations for management or board changes at Novavax.
• With Shah Capital challenging Novavax’s leadership and partnership execution, we’ll now examine how this activism could reshape the company’s investment narrative.

The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 13 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

Novavax Investment Narrative Recap

To own Novavax today, you have to believe its protein based platform and partnership model can convert existing deals with Sanofi, Pfizer, and Takeda into durable cash flows despite revenue volatility and losses. Shah Capital’s latest presentation heightens focus on governance and capital allocation, but it does not yet clearly change the near term product and regulatory catalysts or the key risk around execution by major partners.

The most relevant backdrop to this activism is the May 2024 co exclusive licensing agreement with Sanofi, which brought Novavax an upfront US$500 million and the prospect of up to US$1.2 billion in milestones plus tiered royalties. Shah Capital’s criticism of an “underwhelming” Sanofi partnership goes straight to the heart of this revenue pillar and raises fresh questions about how effectively Novavax is turning that agreement into commercial traction.

Yet beneath these partnership headlines, a less visible but critical risk that investors should be aware of is...

Read the full narrative on Novavax (it's free!)

Novavax's narrative projects $348.5 million revenue and $55.9 million earnings by 2028. This requires a 31.4% yearly revenue decline and an earnings decrease of $366.9 million from $422.8 million today.

Uncover how Novavax's forecasts yield a $13.78 fair value, a 50% upside to its current price.

Exploring Other Perspectives

Some of the lowest estimate analysts painted a far harsher picture, assuming revenues could drop to about US$245.1 million and earnings to roughly US$31.4 million by 2029, even as the Matrix M platform gains broader use. Their pessimism contrasts sharply with more constructive views and Shah Capital’s governance push, reminding you that this new activism could shift both the bearish and optimistic stories from here.

Explore 4 other fair value estimates on Novavax - why the stock might be worth just $13.78!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Novavax research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Novavax research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Novavax's overall financial health at a glance.

Interested In Other Possibilities?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• We've uncovered the 10 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Uncover the next big thing with 25 elite penny stocks that balance risk and reward.
• AI is about to change healthcare. These 34 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com